Agalsidase alfa versus agalsidase beta for the treatment of Fabry disease: an international cohort study

BACKGROUND: Two recombinant enzymes (agalsidase alfa 0.2 mg/kg/every other week and agalsidase beta 1.0 mg/kg/every other week) have been registered for the treatment of Fabry disease (FD), at equal high costs. An independent international initiative compared clinical and biochemical outcomes of the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Med Genet
Autors principals: Arends, Maarten, Biegstraaten, Marieke, Wanner, Christoph, Sirrs, Sandra, Mehta, Atul, Elliott, Perry M, Oder, Daniel, Watkinson, Oliver T, Bichet, Daniel G, Khan, Aneal, Iwanochko, Mark, Vaz, Frédéric M, van Kuilenburg, André B P, West, Michael L, Hughes, Derralynn A, Hollak, Carla E M
Format: Artigo
Idioma:Inglês
Publicat: BMJ Publishing Group 2018
Matèries:
Therapeutics
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5931248/
https://ncbi.nlm.nih.gov/pubmed/29437868
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jmedgenet-2017-104863
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars